|Dr. Roger A. Jeffs Ph.D.||CEO & Director||N/A||N/A||1962|
|Mr. Robert A. Lippe||Chief Operations Officer||728.75k||N/A||1965|
|Dr. Tushar Shah M.D.||Sr. VP of Product Devel.||792.36k||N/A||1961|
|Mr. William R. Kenan Jr.||Co-Founder||N/A||N/A||N/A|
|Dr. Ginger Denison||Co-Founder||N/A||N/A||N/A|
|Mr. Michael Kaseta||Chief Financial Officer||N/A||N/A||1976|
|Jennifer Almond||Director of Investor Relations & Corp. Communications||N/A||N/A||N/A|
|Mr. Russell Schundler||Gen. Counsel & Corp. Sec.||N/A||N/A||1975|
|Mr. Jason Adair||Sr. VP of Corp. Devel. & Strategy||N/A||N/A||1974|
|Ms. Celia Reyes-Hoke||VP of People & Culture||N/A||N/A||N/A|
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. It also distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.
iShares $ Corp Bond ETF USD Dist’s ISS governance QualityScore as of 1 October 2022 is 10. The pillar scores are Audit: 9; Board: 10; Shareholder rights: 6; Compensation: 10.